A case of anti-HMGCR myopathy in a patient with breast cancer and anti-Th/To antibodies
- PMID: 37771688
- PMCID: PMC10530299
- DOI: 10.1093/omcr/omad097
A case of anti-HMGCR myopathy in a patient with breast cancer and anti-Th/To antibodies
Abstract
Statins competitively inhibit the activity of HMGCR (3-hydroxy-3-methylglutaryl coenzyme A reductase), which is a key enzyme in cholesterol synthesis. These are effective drugs for the management of cardiovascular disease and are generally well tolerated but several side effects have been reported. Muscular adverse symptoms are various and, rarely, statin exposure may lead to authentic immune-mediated necrotizing myopathy (IMNM), namely anti-HMGCR myopathy. However, cases of IMNM associated with cancer have been described. We discuss herein a case of IMNM in a patient with breast cancer previously exposed to statins and with the presence of anti-Th/To antibodies without clinical correlation.
© The Author(s) 2023. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Conflict of interest statement
None declared.
Figures
References
-
- Kurashige T. Anti-HMGCR myopathy: clinical and histopathological features, and prognosis. Curr Opin Rheumatol 2021;33:554–62. - PubMed
-
- Allenbach Y, Mammen AL, Benveniste O, Stenzel W, Immune-Mediated Necrotizing Myopathies Working Group . 224th ENMC International Workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14–16 October 2016. Neuromuscul Disord 2018;28:87–99. - PubMed
-
- Needham M, Fabian V, Knezevic W, Panegyres P, Zilko P, Mastaglia FL. Progressive myopathy with upregulation of MHC-I associated with statin therapy. Neuromuscul Disord 2007;17:194–200. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
